阿达木单抗与传统免疫抑制治疗葡萄膜炎(ADVISE)试验
这项随机、非盲法比较 effectiveness 试验纳入227例需要免疫抑制的非感染性中间、后或全葡萄膜炎患者,比较阿达木单抗与传统免疫抑制剂。6个月时阿达木单抗组达到成功激素节省的比例高于传统组(69% vs 54%,OR 1.86,95%CI 1.06-3.25,P=0.029),12个月时成功停用激素的比例也更高(55% vs 40%,OR 1.85,95%CI 1.06-3.19,P=0.028)。
要点
- 6个月成功激素节省率阿达木单抗组69% vs 传统免疫抑制组54%(OR 1.86,95%CI 1.06-3.25,P=0.029)。
- 12个月成功停用激素率阿达木单抗组55% vs 传统组40%(OR 1.85,95%CI 1.06-3.19,P=0.028)。
- 12个月成功激素节省率阿达木单抗组86% vs 传统组77%(OR 1.89,95%CI 0.93-3.83,P=0.077),未达统计学显著。
核心结论
- 对于需要免疫抑制的非感染性中间葡萄膜炎、后葡萄膜炎或全葡萄膜炎患者,与抗代谢药或钙调神经磷酸酶抑制剂相比,阿达木单抗治疗在6个月时获得成功激素节省的患者比例更高,在12个月时成功停用激素的患者比例更高。
研究设计与样本
- 随机、非盲法比较 effectiveness 试验,在美国及国际的学术医学中心和私人执业的葡萄膜炎门诊开展。
- 共227例活动性或近期活动的非感染性中间葡萄膜炎、后葡萄膜炎或全葡萄膜炎且需要免疫抑制的患者被随机分配至阿达木单抗组(n=114)或传统免疫抑制组(n=113)。
- 传统免疫抑制药物包括抗代谢药、钙调神经磷酸酶抑制剂或两者联用。
主要发现
- 6个月随访时,阿达木单抗组69%的患者达到成功激素节省,传统免疫抑制组为54%(OR 1.86,95%CI 1.06-3.25,P=0.029)。
- 12个月时,阿达木单抗组86%的患者达到成功激素节省,传统免疫抑制组为77%(OR 1.89,95%CI 0.93-3.83,P=0.077)。
- 12个月时,阿达木单抗组55%的患者达到成功停用激素,传统免疫抑制组为40%(OR 1.85,95%CI 1.06-3.19,P=0.028)。
关键数值与推荐
- 主要结局成功激素节省定义为:在6个月时,连续两次研究访视(间隔≥28天)泼尼松剂量≤7.5 mg/天(或等效剂量)且葡萄膜炎无活动。
- 其他结局包括1年时成功激素节省以及成功停用激素,后者定义为连续两次研究访视(间隔≥28天)葡萄膜炎无活动且未接受口服糖皮质激素治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis typically are treated with oral corticosteroids and immunosuppressive agents, such as antimetabolites and calcineurin inhibitors. Goals of treatment include suppression of ocular inflammation (inactive disease) and reduction of oral corticosteroids to a prednisone dosage of ≤7.5 mg/day (corticosteroid sparing) or, if possible, discontinuation of prednisone. The anti-tumor necrosis factor monoclonal antibody adalimumab also is used to treat these diseases, but its comparative effectiveness versus conventional agents is unknown. The purpose of this trial was to compare the effectiveness of adalimumab treatment with that of conventional immunosuppressive drugs for uveitis. DESIGN: Randomized, unmasked, comparative effectiveness trial conducted at uveitis clinics at academic medical centers and private practices in the United States and internationally. PARTICIPANTS: Patients with active or recently active noninfectious intermediate uveitis, posterior uveitis, or panuveitis needing immunosuppression. METHODS: Adalimumab versus conventional immunosuppressive drugs (antimetabolites, calcineurin inhibitors, or both). MAIN OUTCOME MEASURES: The primary outcome was successful corticosteroid sparing, defined as inactive uveitis at a prednisone dosage of ≤7.5 mg/day (or its equivalent) for 2 consecutive study visits ≥28 days apart at 6 months. Other outcomes included successful corticosteroid sparing at 1 year and successful corticosteroid discontinuation, defined as inactive uveitis and no oral corticosteroid therapy for 2 consecutive study visits ≥28 days apart. RESULTS: Two hundred twenty-seven participants were randomized to either adalimumab (n = 114) or conventional immunosuppression (n = 113). By 6 months of follow-up, successful corticosteroid sparing occurred in 69% of participants assigned to adalimumab versus 54% assigned to conventional immunosuppression (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.06-3.25; P = 0.029) and by 12 months in 86% of participants assigned to adalimumab versus 77% assigned to conventional immunosuppression (OR, 1.89; 95% CI, 0.93-3.83; P = 0.077). By 12 months, successful corticosteroid discontinuation occurred in 55% of participants assigned to adalimumab versus 40% assigned to conventional immunosuppression (OR, 1.85; 95% CI, 1.06-3.19; P = 0.028). CONCLUSIONS: For patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis requiring immunosuppression, adalimumab treatment resulted in a greater proportion of participants with successful corticosteroid sparing at 6 months and successful corticosteroid discontinuation at 12 months compared with treatment with antimetabolites or calcineurin inhibitors. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Jabs DA, Sugar EA, Burke AE, et al. Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial. Ophthalmology. 2025. PMID: 41077357. doi:10.1016/j.ophtha.2025.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。